Education
About Us
Working with TipRanks
Follow Us
Mind Medicine Inc. (DE:MMQ)
:MMQ
MMQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.29 - €9.80
Previous CloseN/A
Volume187.00
Average Volume (3M)357.00
Market Cap
€634.72M
Enterprise Value€412.10M
Total Cash (Recent Filing)€182.99M
Total Debt (Recent Filing)€41.19M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 12, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,087,944
10 Day Avg. Volume329
30 Day Avg. Volume357
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.31Price Target Upside164.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Financial HealthMindMed's strong balance sheet, which should provide funding three P3 studies, and compelling body of data position it to benefit from these industry tailwinds.
Leadership And ManagementMindMed's leadership team has been strengthened by the appointment of Brandi Roberts as CFO.
Regulatory SupportBreakthrough Therapy designation granted by the FDA to MM120 in GAD supports the company's strategic position.
Bears Say
Clinical Trial RisksWith functional unblinding a known challenge in the field and expectations high, the quality and robustness of the Phase 3 data will be especially important in determining regulatory path and commercial viability.
Regulatory ChallengesFunctional unblinding is a known challenge in the field, making the quality and robustness of the Phase 3 data especially important in determining regulatory path and commercial viability.
Mind Medicine News
MMQ FAQ
What was Mind Medicine Inc.’s price range in the past 12 months?
Mind Medicine Inc. lowest stock price was €4.29 and its highest was €9.80 in the past 12 months.
What is Mind Medicine Inc.’s market cap?
Mind Medicine Inc.’s market cap is €634.72M.
When is Mind Medicine Inc.’s upcoming earnings report date?
Mind Medicine Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 89 days.
How were Mind Medicine Inc.’s earnings last quarter?
Mind Medicine Inc. released its earnings results on Aug 05, 2025. The company reported -€0.429 earnings per share for the quarter, missing the consensus estimate of -€0.326 by -€0.103.
Is Mind Medicine Inc. overvalued?
According to Wall Street analysts Mind Medicine Inc.’s price is currently Undervalued.
Does Mind Medicine Inc. pay dividends?
Mind Medicine Inc. does not currently pay dividends.
What is Mind Medicine Inc.’s EPS estimate?
Mind Medicine Inc.’s EPS estimate is -0.43.
How many shares outstanding does Mind Medicine Inc. have?
Mind Medicine Inc. has 76,087,944 shares outstanding.
What happened to Mind Medicine Inc.’s price movement after its last earnings report?
Mind Medicine Inc. reported an EPS of -€0.429 in its last earnings report, missing expectations of -€0.326. Following the earnings report the stock price went up 2.117%.
Which hedge fund is a major shareholder of Mind Medicine Inc.?
Currently, no hedge funds are holding shares in DE:MMQ
Mind Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.31 (164.38% Upside)
€22.31 (164.38% Upside)
Blogger Sentiment
Bullish
DE:MMQ Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.05%
12-Months-Change
Fundamentals
Return on Equity
-59.11%
Trailing 12-Months
Asset Growth
-1.14%
Trailing 12-Months
Company Description
Mind Medicine Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
MMQ Company Deck
MMQ Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.View all DE:MMQ earnings summariesMMQ Stock 12 Month Forecast
Average Price Target
€22.31
▲(164.38% Upside)
Technical Analysis
Altimmune
―
Sana Biotechnology
―
Verve Therapeutics
―
ATAI Life Sciences
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
2.57% Insiders
5.42%
Mutual Funds
0.17% Other Institutional Investors
84.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---